Modulation of in vivo cardiac hypertrophy with insulin-like growth factor-1 and angiotensin-converting enzyme inhibitor: relationship between change in myosin isoform and progression of left ventricular dysfunction
Yoshitaka Iwanaga, MD, PhDa,
Yasuki Kihara, MD, PhD, FACCa,
Takeshi Yoneda, MDa,
Takeshi Aoyama, MD, PhDa and
Shigetake Sasayama, MD, PhD, FACCa
a Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
View larger version (16K):
[in a new window]
|
Figure 1 The effect of human recombinant IGF-1 and temocapril on animal survival. Kaplan-Meier survival curves for the IGF-1-treated group (n = 8; open circles), the temocapril-treated group (n = 10; filled circles), and the control group (n = 10; open inverted triangles). The IGF-1, temocapril, or placebo was administrated from 11 weeks of age. *p < 0.01 or #p < 0.05 vs. control (log-rank test).
|
|
View larger version (24K):
[in a new window]
|
Figure 2 The effect of human recombinant IGF-1 and temocapril on echocardiographic data. The graphs show serial transthoracic echocardiographic measurements, LV end-diastolic dimension (LV EDD) (A); estimated LV weight to body weight ratio (LV/BW) (B); relative wall thickness (RWT) (C); and LV fractional shortening (FS) (D), for the IGF-1-treated group (n = 8; open circles), the temocapril-treated group (n = 10; filled circles), and the control group (n = 10; open inverted triangles). Values are expressed as mean ± SEM. *p < 0.05.
|
|
View larger version (31K):
[in a new window]
|
Figure 3 Results of measurement of the MHC mRNA in the LV myocardium of each group. The ratios of MHC isoform mRNA and total MHC mRNA (A) were measured by "Hot" RT-PCR (D, upper panel) and Northern blot analysis (D, lower panel), respectively. The amount of  (B) or ß (C) isoform mRNA was calculated from these measures. Values are expressed as mean ± SEM. *p < 0.05.
|
|
|
